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Letters to the Editor
Effects of N-3 Fatty Acids
on Postoperative Atrial Fibrillation
Following Coronary Artery Bypass Surgery
We read with considerable interest the recent contribution by Calò
et al. (1) about the reduced incidence of postoperative atrial
fibrillation (AF) after administration of n-3 polyunsaturated fatty
acids (PUFAs) in patients undergoing coronary artery bypass
surgery (CABG). Even though the investigators discuss the
potential role of inflammation in this setting we consider that some
important issues merit further clarification.
First, 19 of the studied patients were subjected to off-pump
surgery, a procedure considered to be associated with a lesser
oxidative and inflammatory response (2). Bearing in mind the
hypothesis that postoperative AF may be reduced by off-pump
CABG (3), it would be meaningful to examine whether there was
a difference in the incidence of postoperative AF in this subset of
patients.
In addition, it has been observed that the peak incidence of AF
on the second or third postoperative day coincides with the peak of
inflammatory markers such as C-reactive protein (CRP) and
complement-CRP complexes (4). Recently, Abdelhadi et al. (5)
confirmed this association, demonstrating a more pronounced and
prolonged increase in white blood cell counts of patients who
developed postoperative AF. Thus, to validate the anti-inflammatory
effects of PUFAs someone could investigate the variation of simple
inflammatory indexes in the postoperative period. If Calò et al. have
some available data on this issue it would be of interest to perform
comparisons between the two groups.
Of note, more than one-half the total study population was
taking statins perioperatively (1). Even though there were no
differences regarding statin administration between the studied
groups, the investigators could mention some data on potential
differences in the incidence of postoperative AF within each group.
Statins may exert beneficial pleiotropic effects on atrial remodeling,
reducing the burden of the arrhythmia. It has also been indicated
that statin therapy reduces the incidence of arrhythmias after
CABG, although no specific data on AF was reported (6).
Recently, Auer et al. (7) demonstrated a reduced incidence of AF
after cardiac operation in patients receiving statins, but 44.7% of
these had been subjected to valve surgery.
Accumulating evidence suggests that inflammation augments
oxidative stress and vice versa, whereas oxidative stress seems to
play an important role in atrial remodeling (2,8). Specifically, it has
been shown that oral vitamin C administration significantly
reduces the incidence of postoperative AF in CABG patients (8).
Taking into account that PUFAs can attenuate oxidative stress in
humans (9), it is reasonable to assume that their antioxidant action
may contribute to their favorable effect on postoperative AF.
Finally, we concur with the view of Calò et al. that adminis-
tration of PUFAs merits further evaluation in other forms of AF,
but, as suggested by a recent study that reported no association
between PUFA consumption from fish and the risk of AF (10),
careful selection of the studied population should be performed.
*Panagiotis Korantzopoulos, MD
Theofilos M. Kolettis, MD, PhD
John A. Goudevenos, MD, FACC, FESC
*Department of Internal Medicine
Division of Cardiology
University of Ioannina Medical School
45110 Ioannina
Greece
E-mail: pkor@oneway.gr, pan-kor@mailbox.gr
doi:10.1016/j.jacc.2005.10.026
REFERENCES
1. Calò L, Bianconi L, Colivicchi F, et al. N-3 fatty acids for the
prevention of atrial fibrillation after coronary artery bypass surgery. A
randomized, controlled trial. J Am Coll Cardiol 2005;45:1723–8.
2. Matata BM, Sosnowski AW, Galinanes M. Off-pump bypass graft
operation significantly reduces oxidative stress and inflammation. Ann
Thorac Surg 2000;69:785–91.
3. Archbold RA, Curzen NP. Off-pump coronary artery bypass graft
surgery: the incidence of postoperative atrial fibrillation. Heart 2003;
89:1134–7.
4. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the
complement system during and after cardiopulmonary bypass surgery:
postsurgery activation involves C-reactive protein and is associated
with postoperative arrhythmia. Circulation 1997;96:3542–8.
5. Abdelhadi RH, Gurm HS, Van Wagoner DR, Chung MK. Relation
of an exaggerated rise in white blood cells after coronary bypass or
cardiac valve surgery to development of atrial fibrillation postopera-
tively. Am J Cardiol 2004;93:1176–8.
467JACC Vol. 47, No. 2, 2006 Correspondence
January 17, 2006:464–71
6. Dotani MI, Elnicki M, Jain AC, Gibson CM. Effect of preoperative
statin therapy and cardiac outcomes after coronary bypass grafting.
Am J Cardiol 2000;86:1128–30.
7. Auer J, Weber T, Berent R, et al. Use of HMG-coenzyme-a–
reductase inhibitors (statins) and risk reduction of atrial fibrillation
after cardiac surgery: results of the SPAAF study—a randomised
placebo-controlled study (abstr). European Society of Cardiology
Annual Congress, Munich 2004. Abstract book, p. 353.
8. Carnes CA, Chung MK, Nakayama T, et al. Ascorbate attenuates
atrial pacing-induced peroxynitrite formation and electrical remodel-
ing and decreases the incidence of postoperative atrial fibrillation. Circ
Res 2001;89:e32–8.
9. Mori TA, Woodman RJ, Burke V, et al. Effect of eicosapentaenoic
acid and docosahexaenoic acid on oxidative stress and inflammatory
markers in treated hypertensive type 2 diabetic patients. Free Radic
Biol Med 2003;35:772–81.
10. Frost L, Vestergaard P. N-3 fatty acids consumed from fish and risk of
atrial fibrillation or flutter: the Danish Diet, Cancer, and Health
Study. Am J Clin Nutr 2005;81:50–4.
REPLY
In our study (1) we observed a reduced incidence of atrial
fibrillation (AF) following coronary artery bypass surgery in pa-
tients receiving polyunsaturated fatty acids (PUFAs). The way
these compounds could have determined this result is, at present,
only speculative. Indeed, PUFAs have been demonstrated to have
a direct anti-arrhythmic effect in different laboratory models, but
the importance of a concurrent (or prevalent) anti-inflammatory
action cannot be excluded. In fact, PUFAs have anti-inflammatory
properties (2), and inflammation, as correctly pointed out by Dr.
Korantzopoulos and colleagues can play a fundamental role in
postcardiac surgery AF. Actually, the efficacy of an anti-inflammatory
therapy in this setting is still not clear owing to conflicting reports.
Whereas a single postinduction steroid administration was shown
to prevent postoperative AF (3), a similar protocol was found
ineffective in other hands (4). The debate on this subject is thus
still open, but unfortunately a further contribution cannot be
obtained by our study, because C-reactive protein (CRP) levels or
other inflammatory indexes were not routinely collected in our
patients.
Concerning off-pump surgery that could carry a lower risk of
AF due to a lesser oxidative and inflammatory response, aside from
reports supporting this assumption (5) there are other studies that
do not confirm this finding (6). In our study the incidence of AF
was similar in patients receiving off-pump surgery (26.3% of 19
cases) and those submitted to on-pump surgery (24.1% of 141
cases). However, our population is too scarce to draw any conclu-
sion on this subject.
Statins have been reported to prevent AF both after cardiac
surgery (7) and after electrical cardioversion (8), possibly by their
pleiotropic anti-inflammatory action. In our examination we did
not observe any difference in AF incidence between patients on
statins (24.2% of 91 patients) and those not on statins (24.6% of 61
patients). This could be due to the fact that the mean dose of
statins in our patients was low (15.3 9.2 mg/day simvastatin and
13.2  7.5 mg/day atorvastatin) and the anti-inflammatory and
thus, possibly, anti-arrhythmic effect of statins seems to be related
to the dose. In fact, a recent study reported a significant decrease
of CPR (36.4%) with atorvastatin 80 mg but not with pravastatin
40 mg (5.2%) (9).
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Serum Erythropoietin Levels and Infarct Size
With great interest we read the recent study by Namiuchi et al. (1)
showing an association between high serum erythropoietin levels
and smaller infarct size in patients with acute myocardial infarction
(MI) undergoing primary angioplasty.
Although originally considered a hematopoietic hormone,
erythropoietin (EPO) has been shown to act as a pleiotropic
survival and growth factor (2). There is accumulating evidence for
a protective role of EPO in the heart. We and others have
demonstrated that exogenous EPO administration in rodent
ischemia-reperfusion models leads to reduced infarct size and
inhibition of apoptosis (3,4).
Namiuchi et al. (1) suggested that endogenous EPO might also be
protective against ischemia-reperfusion injury in humans. However,
elevated EPO levels could also be a direct reflection of the disease
severity. Serum EPO is elevated in chronic heart failure (CHF)
patients, and this increase is related to the progression of the disease
(5). Our group has shown that, in these patients, elevated plasma
EPO levels are associated with an impaired prognosis, independent of
hemoglobin levels and other established markers of CHF severity (6).
Of note, in the study by Namiuchi et al. (1), MI patients with higher
EPO levels were found to have significantly higher serum levels of
B-type natriuretic peptide (BNP), a sign of hemodynamic impair-
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